324 related articles for article (PubMed ID: 35489737)
21. Clinical and mutational profiles of adult medulloblastoma groups.
Wong GC; Li KK; Wang WW; Liu AP; Huang QJ; Chan AK; Poon MF; Chung NY; Wong QH; Chen H; Chan DTM; Liu XZ; Mao Y; Zhang ZY; Shi ZF; Ng HK
Acta Neuropathol Commun; 2020 Nov; 8(1):191. PubMed ID: 33172502
[TBL] [Abstract][Full Text] [Related]
22. Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma.
Zhukova N; Ramaswamy V; Remke M; Pfaff E; Shih DJ; Martin DC; Castelo-Branco P; Baskin B; Ray PN; Bouffet E; von Bueren AO; Jones DT; Northcott PA; Kool M; Sturm D; Pugh TJ; Pomeroy SL; Cho YJ; Pietsch T; Gessi M; Rutkowski S; Bognar L; Klekner A; Cho BK; Kim SK; Wang KC; Eberhart CG; Fevre-Montange M; Fouladi M; French PJ; Kros M; Grajkowska WA; Gupta N; Weiss WA; Hauser P; Jabado N; Jouvet A; Jung S; Kumabe T; Lach B; Leonard JR; Rubin JB; Liau LM; Massimi L; Pollack IF; Shin Ra Y; Van Meir EG; Zitterbart K; Schüller U; Hill RM; Lindsey JC; Schwalbe EC; Bailey S; Ellison DW; Hawkins C; Malkin D; Clifford SC; Korshunov A; Pfister S; Taylor MD; Tabori U
J Clin Oncol; 2013 Aug; 31(23):2927-35. PubMed ID: 23835706
[TBL] [Abstract][Full Text] [Related]
23. Transcriptional repressor REST drives lineage stage-specific chromatin compaction at
Dobson THW; Tao RH; Swaminathan J; Maegawa S; Shaik S; Bravo-Alegria J; Sharma A; Kennis B; Yang Y; Callegari K; Haltom AR; Taylor P; Kogiso M; Qi L; Khatua S; Goldman S; Lulla RR; Fangusaro J; MacDonald TJ; Li XN; Hawkins C; Rajaram V; Gopalakrishnan V
Sci Signal; 2019 Jan; 12(565):. PubMed ID: 30670636
[TBL] [Abstract][Full Text] [Related]
24. Molecular Classification of Medulloblastoma.
Kijima N; Kanemura Y
Neurol Med Chir (Tokyo); 2016 Nov; 56(11):687-697. PubMed ID: 27238212
[TBL] [Abstract][Full Text] [Related]
25. Clinicopathological characteristics, molecular subgrouping, and expression of miR-379/miR-656 cluster (C14MC) in adult medulloblastomas.
Kaur K; Kakkar A; Kumar A; Purkait S; Mallick S; Suri V; Sharma MC; Julka PK; Gupta D; Suri A; Sarkar C
J Neurooncol; 2016 Dec; 130(3):423-430. PubMed ID: 27576698
[TBL] [Abstract][Full Text] [Related]
26. Targeted treatment for sonic hedgehog-dependent medulloblastoma.
Kieran MW
Neuro Oncol; 2014 Aug; 16(8):1037-47. PubMed ID: 24951114
[TBL] [Abstract][Full Text] [Related]
27. Advanced MRI Findings in Medulloblastomas: Relationship to Genetic Subtypes, Histopathology, and Immunohistochemistry.
Reis J; Stahl R; Zimmermann H; Ruf V; Thon N; Kunz M; Liebig T; Forbrig R
J Neuroimaging; 2021 Mar; 31(2):306-316. PubMed ID: 33465267
[TBL] [Abstract][Full Text] [Related]
28. Simplified Molecular Subtyping of Medulloblastoma for Reduced Cost and Improved Turnaround Time.
Shuangshoti S; Tadadontip P; Techavichit P; Thorner PS; Shuangshoti S; Teerapakpinyo C
Appl Immunohistochem Mol Morphol; 2020 Aug; 28(7):538-543. PubMed ID: 31343993
[TBL] [Abstract][Full Text] [Related]
29. Clinicomorphological and molecular analysis of medulloblastoma and association with survival: A single tertiary care center experience.
Badiger S; Gudipati A; Uppin M; Konatam ML; Yeramneni VK; Bhattacharjee S; Saradhi MV; Patnaik S; Irukulla M
J Cancer Res Ther; 2023 Jan; 19(Suppl 2):S592-S602. PubMed ID: 38384024
[TBL] [Abstract][Full Text] [Related]
30. Proteomic profiling of medulloblastoma reveals novel proteins differentially expressed within each molecular subgroup.
Narayan V; Jaiswal J; Sugur H; Sd S; Rao S; Chatterjee A; Gowda H; A A; Somanna S; Santosh V
Clin Neurol Neurosurg; 2020 Sep; 196():106028. PubMed ID: 32580068
[TBL] [Abstract][Full Text] [Related]
31. Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition.
Kool M; Jones DT; Jäger N; Northcott PA; Pugh TJ; Hovestadt V; Piro RM; Esparza LA; Markant SL; Remke M; Milde T; Bourdeaut F; Ryzhova M; Sturm D; Pfaff E; Stark S; Hutter S; Seker-Cin H; Johann P; Bender S; Schmidt C; Rausch T; Shih D; Reimand J; Sieber L; Wittmann A; Linke L; Witt H; Weber UD; Zapatka M; König R; Beroukhim R; Bergthold G; van Sluis P; Volckmann R; Koster J; Versteeg R; Schmidt S; Wolf S; Lawerenz C; Bartholomae CC; von Kalle C; Unterberg A; Herold-Mende C; Hofer S; Kulozik AE; von Deimling A; Scheurlen W; Felsberg J; Reifenberger G; Hasselblatt M; Crawford JR; Grant GA; Jabado N; Perry A; Cowdrey C; Croul S; Zadeh G; Korbel JO; Doz F; Delattre O; Bader GD; McCabe MG; Collins VP; Kieran MW; Cho YJ; Pomeroy SL; Witt O; Brors B; Taylor MD; Schüller U; Korshunov A; Eils R; Wechsler-Reya RJ; Lichter P; Pfister SM;
Cancer Cell; 2014 Mar; 25(3):393-405. PubMed ID: 24651015
[TBL] [Abstract][Full Text] [Related]
32. Genetic Markers as Predictors for Response to Treatment and Possible Therapeutic Targets in Medulloblastoma.
Pérez-Pineda PL; Ortiz-Butrón R; Pérez-De Marcos JC; Hernández-Regino LM; Zapata-Tarrés MM; Torres-Espíndola LM
CNS Neurol Disord Drug Targets; 2023; 22(5):634-642. PubMed ID: 35579144
[TBL] [Abstract][Full Text] [Related]
33. Subgroup-Enriched Pathways and Kinase Signatures in Medulloblastoma Patient-Derived Xenografts.
Leskoske KL; Garcia-Mansfield K; Sharma R; Krishnan A; Rusert JM; Mesirov JP; Wechsler-Reya RJ; Pirrotte P
J Proteome Res; 2022 Sep; 21(9):2124-2136. PubMed ID: 35977718
[TBL] [Abstract][Full Text] [Related]
34. Molecular characterization of medulloblastomas with extensive nodularity (MBEN).
Korshunov A; Sahm F; Stichel D; Schrimpf D; Ryzhova M; Zheludkova O; Golanov A; Lichter P; Jones DTW; von Deimling A; Pfister SM; Kool M
Acta Neuropathol; 2018 Aug; 136(2):303-313. PubMed ID: 29569031
[TBL] [Abstract][Full Text] [Related]
35. Medulloblastoma in the age of molecular subgroups: a review.
Juraschka K; Taylor MD
J Neurosurg Pediatr; 2019 Oct; 24(4):353-363. PubMed ID: 31574483
[TBL] [Abstract][Full Text] [Related]
36. Expression of GNAS, TP53, and PTEN Improves the Patient Prognostication in Sonic Hedgehog (SHH) Medulloblastoma Subgroup.
da Silva LS; Mançano BM; de Paula FE; Dos Reis MB; de Almeida GC; Matsushita M; Junior CA; Evangelista AF; Saggioro F; Serafini LN; Stavale JN; Malheiros SMF; Lima M; Hajj GNM; de Lima MA; Taylor MD; Leal LF; Reis RM
J Mol Diagn; 2020 Jul; 22(7):957-966. PubMed ID: 32380172
[TBL] [Abstract][Full Text] [Related]
37. Pik3ca mutations significantly enhance the growth of SHH medulloblastoma and lead to metastatic tumour growth in a novel mouse model.
Niesen J; Ohli J; Sedlacik J; Dührsen L; Hellwig M; Spohn M; Holsten T; Schüller U
Cancer Lett; 2020 May; 477():10-18. PubMed ID: 32112900
[TBL] [Abstract][Full Text] [Related]
38. METTL3 regulates m
Zhang ZW; Teng X; Zhao F; Ma C; Zhang J; Xiao LF; Wang Y; Chang M; Tian Y; Li C; Zhang Z; Song S; Tong WM; Liu P; Niu Y
Cell Rep; 2022 Oct; 41(4):111530. PubMed ID: 36288719
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of WNT signaling attenuates self-renewal of SHH-subgroup medulloblastoma.
Rodriguez-Blanco J; Pednekar L; Penas C; Li B; Martin V; Long J; Lee E; Weiss WA; Rodriguez C; Mehrdad N; Nguyen DM; Ayad NG; Rai P; Capobianco AJ; Robbins DJ
Oncogene; 2017 Nov; 36(45):6306-6314. PubMed ID: 28714964
[TBL] [Abstract][Full Text] [Related]
40. Approach to molecular subgrouping of medulloblastomas: Comparison of NanoString nCounter assay versus combination of immunohistochemistry and fluorescence in-situ hybridization in resource constrained centres.
Kaur K; Jha P; Pathak P; Suri V; Sharma MC; Garg A; Suri A; Sarkar C
J Neurooncol; 2019 Jul; 143(3):393-403. PubMed ID: 31104222
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
